Provided by Tiger Fintech (Singapore) Pte. Ltd.

Leap Therapeutics Inc

0.4090
+0.00902.25%
Pre-market: 0.3864-0.0226-5.53%08:32 EDT
Volume:261.73K
Turnover:105.63K
Market Cap:16.87M
PE:-0.24
High:0.4179
Open:0.3980
Low:0.3750
Close:0.4000
Loading ...

Leap Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

BRIEF-Leap Therapeutics Q1 Net Income USD -15.435 Million

Reuters
·
13 May

BRIEF-Leap Therapeutics - Announces 50% Workforce Reduction In Strategic Restructuring - SEC Filing

Reuters
·
13 May

Leap Therapeutics Inc - Announces 50% Workforce Reduction in Strategic Restructuring - SEC Filing

THOMSON REUTERS
·
13 May

Leap Therapeutics - Q1 Loss per Share $0.37

THOMSON REUTERS
·
13 May

Leap Therapeutics Reports Q1 2025 Net Loss of $15.4M, Up from $13.8M in Q1 2024, Due to Increased R&D Expenses

Reuters
·
13 May

Leap Therapeutics Q1 EPS USD -0.37

THOMSON REUTERS
·
13 May

Leap Therapeutics Inc: Has Reduced Its Workforce by Approximately 50%

THOMSON REUTERS
·
13 May

Leap Therapeutics Inc: Strategic Restructuring to Prioritize Clinical Focus on Development of Sirexatamab in Crc

THOMSON REUTERS
·
13 May

Leap Therapeutics Q1 Operating Expenses USD 15.917 Million

THOMSON REUTERS
·
13 May

Leap Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
09 May

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

PR Newswire
·
26 Apr

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

PR Newswire
·
15 Apr

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Benzinga
·
27 Mar

Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial

MT Newswires Live
·
26 Mar

BRIEF-Leap Therapeutics Reports Fourth Quarter And FY 2024 Results

Reuters
·
26 Mar

Leap Therapeutics Q4 Operating Expenses USD 16.125 Million

THOMSON REUTERS
·
26 Mar

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire
·
26 Mar

Leap Therapeutics Reports Positive Updated Data From Sirexatamab Colorectal Cancer Study

THOMSON REUTERS
·
26 Mar

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

PR Newswire
·
26 Mar